• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/11/21 4:30:55 PM ET
    $BBI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BBI alert in real time by email
    SC 13G/A 1 sc13ga207422bbi_02052021.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G

     UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

    (Amendment No. 2)1

     

    Brickell Biotech, Inc.

     (Name of Issuer)

    Common Stock, $0.01 par value

     (Title of Class of Securities)

    10802T105

     (CUSIP Number)

    December 31, 2020

     (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐  Rule 13d-1(b)

       ☒  Rule 13d-1(c)

       ☐  Rule 13d-1(d)

     

     

     

    1              The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    2

    CUSIP No. 10802T105

      1   NAME OF REPORTING PERSON  
             
            BVF I GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    3

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Fund II, L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    4

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            BVF II GP LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    5

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            Biotechnology Value Trading Fund OS LP  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            PN  

      

    6

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners OS Ltd.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Cayman Islands  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    7

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            BVF GP HOLDINGS LLC  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            OO  

      

    8

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            BVF Partners L.P.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            PN, IA  

      

    9

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            BVF Inc.  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            Delaware  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            CO  

      

    10

    CUSIP No. 10802T105

     

      1   NAME OF REPORTING PERSON  
             
            Mark N. Lampert  
      2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
            (b) ☐
               
      3   SEC USE ONLY    
               
                 
      4   CITIZENSHIP OR PLACE OF ORGANIZATION  
             
            United States  
    NUMBER OF   5   SOLE VOTING POWER  
    SHARES          
    BENEFICIALLY         - 0 -  
    OWNED BY   6   SHARED VOTING POWER  
    EACH          
    REPORTING         - 0 -  
    PERSON WITH   7   SOLE DISPOSITIVE POWER  
             
              - 0 -  
        8   SHARED DISPOSITIVE POWER  
               
              - 0 -  
      9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
             
            - 0 -  
      10   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES     ☐
           
               
      11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
             
            0%  
      12   TYPE OF REPORTING PERSON  
             
            IN  

      

    11

    CUSIP No. 10802T105

    Item 1(a).Name of Issuer:

     

    Brickell Biotech, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer's Principal Executive Offices:

     

    5777 Central Avenue, Suite 102

    Boulder, Colorado 80301

     

    Item 2(a).Name of Person Filing
    Item 2(b).Address of Principal Business Office or, if None, Residence
    Item 2(c).Citizenship

     

    Biotechnology Value Fund, L.P. (“BVF”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF I GP LLC (“BVF GP”),

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Fund II, L.P. (“BVF2”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF II GP LLC (“BVF2 GP”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    12

    CUSIP No. 10802T105

    BVF Partners OS Ltd. (“Partners OS”)

    PO Box 309 Ugland House

    Grand Cayman, KY1-1104

    Cayman Islands

    Citizenship: Cayman Islands

     

    BVF GP Holdings LLC (“BVF GPH”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Partners L.P. (“Partners”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    BVF Inc.

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: Delaware

     

    Mark N. Lampert (“Mr. Lampert”)

    44 Montgomery St., 40th Floor

    San Francisco, California 94104

    Citizenship: United States

     

    Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    Item 2(d).Title of Class of Securities:

     

    Common stock, $0.01 par value per share (the “Shares”).

     

    Item 2(e).CUSIP Number:

     

    10802T105

     

    13

    CUSIP No. 10802T105

    Item 3.If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        /x/ Not applicable.
           
      (a) / / Broker or dealer registered under Section 15 of the Exchange Act.
           
      (b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
           
      (c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
           
      (d) / / Investment company registered under Section 8 of the Investment Company Act.
           
      (e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
           
      (f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
           
      (g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
           
      (h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
           
      (i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
           
      (j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).  
           
      (k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4.Ownership

     

    As of the close of business on December 31, 2020, the Reporting Persons no longer beneficially owned any Shares of the Issuer.

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

     

    14

    CUSIP No. 10802T105

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 14, 2020.

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable.

     

    Item 10.Certifications.

     

    By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    15

    CUSIP No. 10802T105

    SIGNATURE

     

    After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Dated: February 11, 2021

     

    BIOTECHNOLOGY VALUE FUND, L.P.   BIOTECHNOLOGY VALUE TRADING FUND OS LP
           
    By: BVF I GP LLC., its general partner   By: BVF Partners L.P., its investment manager
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF I GP LLC      
          BVF GP HOLDINGS LLC
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            Chief Executive Officer
             
    BIOTECHNOLOGY VALUE FUND II, L.P.    
          BVF PARTNERS L.P.
    By: BVF II GP LLC, its general partner    
          By: BVF Inc., its general partner
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF II GP LLC      
          BVF INC.
    By: /s/ Mark N. Lampert    
      Mark N. Lampert   By: /s/ Mark N. Lampert
      Chief Executive Officer     Mark N. Lampert
            President
             
    BVF PARTNERS OS LTD.      
          /s/ Mark N. Lampert
    By: BVF Partners L.P., its sole member   MARK N. LAMPERT
    By: BVF Inc., its general partner    
             
    By:

    /s/ Mark N. Lampert

         
      Mark N. Lampert      
      President      

    16

      

    Get the next $BBI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BBI

    DatePrice TargetRatingAnalyst
    3/8/2022Outperform
    William Blair
    1/18/2022$2.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BBI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Brickell Biotech Inc. (Amendment)

      SC 13G/A - Brickell Biotech, Inc. (0000819050) (Subject)

      2/3/22 3:37:26 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Brickell Biotech, Inc. (Amendment)

      SC 13G/A - Brickell Biotech, Inc. (0000819050) (Subject)

      11/3/21 12:45:26 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Brickell Biotech, Inc.

      SC 13G - Brickell Biotech, Inc. (0000819050) (Subject)

      7/22/21 8:59:28 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    SEC Filings

    See more
    • SEC Form 10-Q filed by Brickell Biotech Inc.

      10-Q - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      11/10/22 7:19:43 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      11/10/22 4:10:26 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

      9/20/22 4:48:21 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Floor & Decor Holdings, Inc. (NYSE: FND)

      NOTE TO EDITORS: The Following is an Investment Opinion Issued by Spruce Point Capital Management Believes That Floor & Decor's Ballooning Capital Expenditures and New Store Operating Costs in Lower Income and New Geographic Markets Will Severely Impair its Earnings Potential Identifies at Least Ten Other Areas of Misperception That Suggest Floor & Decor's Challenges Are Structural and Are Not Cyclical or Easily Fixed Provides Evidence That Floor & Decor Recently Made Revisions to Key Revenue Claims, Numerous Omissions of Past Disclosures, Changes to Accounting Policy Language and Modifications to Business Practices That Obscure its Growing Challenges Provides Evidence That CEO Thom

      7/1/24 9:00:00 AM ET
      $CRI
      $FND
      $LIN
      $BBI
      Apparel
      Consumer Discretionary
      RETAIL: Building Materials
      Major Chemicals
    • Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

      FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing On track to report SAD and MAD topline results from FRTX-02 Phase 1 study by early 2023 BOULDER, Colo., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and groundbreaking prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it has initiated the multiple ascending dose ("MAD") portion of the ongoing Phase 1 clinical trial

      9/13/22 8:00:00 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

      New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol "FRTX" on September 8, 2022 Company also establishes Scientific Advisory Board consisting of renowned autoimmune and inflammatory disease experts to provide strategic guidance for the research and development of FRTX's novel pipeline BOULDER, Colo., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI) today announced that it has changed its name to Fresh Tracks Therapeutics, Inc. ("FRTX" or the "Company"). The new name, logo, website, and brand

      9/7/22 8:00:00 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Hardy Reginald L

      4 - Brickell Biotech, Inc. (0000819050) (Issuer)

      5/17/22 5:18:21 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Samant Vijay B

      4 - Brickell Biotech, Inc. (0000819050) (Issuer)

      5/17/22 5:16:32 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Lyons Gary A

      4 - Brickell Biotech, Inc. (0000819050) (Issuer)

      5/17/22 5:15:05 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Financials

    Live finance-specific insights

    See more
    • Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

      Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early preclinical stage studies BOULDER, Colo., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced financial results for the second qua

      8/11/22 4:05:00 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

      BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its second quarter financial results on Thursday, August 11th. Brickell's management will host a conference call and webcast at 4:30 p.m. EDT that same day to discuss the financial results and recent corporate highlights. To access the call, please dial 1-844-826-3035 (U.S.) or 1-412-317-5195 (international) and provide the conferenc

      8/2/22 4:05:00 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Brickell Biotech Reports First Quarter 2022 Financial Results and Provides Corporate Update

      Completed sale of sofpironium bromide to Botanix Pharmaceuticals for up to $9 million in upfront and potential near-term regulatory milestone payments, $168 million in potential future regulatory and sales milestone payments, plus tiered earnout payments on net sales Sale reflects Brickell's new business strategy and commitment to developing its pipeline of novel, potential first-in-class treatments in immunology and inflammation On track to initiate a Phase 1 study of BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases, in the second quarter of 2022, with SAD and MAD topline results expected by early 2023 BOULDER, Colo., May 12, 2022 (GLOBE

      5/12/22 4:01:00 PM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Brickell Biotech

      William Blair initiated coverage of Brickell Biotech with a rating of Outperform

      3/8/22 6:55:45 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Brickell Biotech with a new price target

      HC Wainwright & Co. initiated coverage of Brickell Biotech with a rating of Buy and set a new price target of $2.00

      1/18/22 6:11:49 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBI
    Leadership Updates

    Live Leadership Updates

    See more
    • Brickell Biotech Expands Leadership Team, Appointing Dr. Monica Luchi as Chief Medical Officer

      BOULDER, Colo., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of dermatologic, autoimmune and other debilitating diseases, today announced that it has appointed Monica Luchi, MD, FACR, MBA to the newly created role of Chief Medical Officer. In this new role, Dr. Luchi will oversee the Company's clinical development strategy and medical affairs functions. "We are delighted to have Dr. Luchi join our team at this transformative point in our Company's history. Her tremendou

      9/1/21 7:05:00 AM ET
      $BBI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care